What if we could tackle aging at its source? Rubedo Life Sciences, a LongeVC portfolio company, is taking a bold step toward that vision with the announcement of clinical development plans for RLS-1496. This first-in-class GPX4 modulator targets aging cells and their surrounding tissues, aiming to address the root causes of age-related diseases.
Set to begin Phase I clinical trials in the Netherlands this spring, RLS-1496 represents a promising shift in how we approach chronic conditions tied to aging. By focusing on cellular damage and dysfunction, Rubedo’s work could reshape treatment for diseases such as cancer, metabolic syndrome, and neurodegenerative disorders.
This milestone was announced at the 12th Annual Dermatology Summit, where Rubedo’s CEO, Dr. Frederick Beddingfield, highlighted the potential of longevity science as a $600 billion global opportunity. The event also featured Chief Scientific Officer Dr. Marco Quarta, who shared details on the upcoming trial and the company’s vision for advancing healthspan innovation.
As the global population continues to age, breakthroughs like RLS-1496 are vital for improving not just how long we live, but how well we live.
Learn more about Rubedo Life Sciences and their work here. The full announcement is here.
Set to begin Phase I clinical trials in the Netherlands this spring, RLS-1496 represents a promising shift in how we approach chronic conditions tied to aging. By focusing on cellular damage and dysfunction, Rubedo’s work could reshape treatment for diseases such as cancer, metabolic syndrome, and neurodegenerative disorders.
This milestone was announced at the 12th Annual Dermatology Summit, where Rubedo’s CEO, Dr. Frederick Beddingfield, highlighted the potential of longevity science as a $600 billion global opportunity. The event also featured Chief Scientific Officer Dr. Marco Quarta, who shared details on the upcoming trial and the company’s vision for advancing healthspan innovation.
As the global population continues to age, breakthroughs like RLS-1496 are vital for improving not just how long we live, but how well we live.
Learn more about Rubedo Life Sciences and their work here. The full announcement is here.